medigraphic.com
ISSN 1561-3011 (Electronic)

2013, Number 2

<< Back Next >>

Rev Cubana Invest Bioméd 2013; 32 (2)

Low concentrations of cholesterol associated with high density lipoproteins (HDL), a risk factor to consider in women with ischemic hearth disease

Llanes EJR, Ortega TY, Rodríguez RY, Céspedes G, Bacallao F, Solis M, Batista M, Alpízar BN, Heres F

Language: Spanish
References: 25
Page: 147-158
PDF size: 239.92 Kb.


ABSTRACT

Background: Ischemic heart disease is one of the main causes of death in women, both in Cuba and in the world.
Objective: The objective of this study was to determine whether low cholesterol concentrations, associated with high density lipoproteins, represent a risk factor to consider in women with ischemic heart disease.
Methods: An observational, transversal study was conducted in 727 women during the period from January 2010 to December 2012. The percent of women with or without ischemic heart disease (IHD) and different ranges of HDL - C levels (normal or pathological) was determined.
Results: Women with IHD had a mean age and a waist-hip ratio within the range of cardiovascular risk. Triglycerides and VLDL-C levels were significantly higher (p ‹0.05 *), related to a significant decrease of HDL- C levels (p ‹0.05 *) in women with IHD (groups B and C) when compared with the control group. Also, a significant association (p‹0, 05*) was found between the low levels of HDL- C levels, with presence of ischemic heart disease, hypertriglyceridemia and antecent of myocardial revascularization surgery.
Conclusions: Low HDL-C levels are associated with the presence of ischemic heart disease and hypertriglyceridemia. Therefore, the control of HDL- C levels represents a therapeutic target which helps to reduce major cardiovascular events. Moreover, the presence of other risk factors such as age and overweight could influence the development of these events.


REFERENCES

  1. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124:2114-54. 2- Franco M, Cooper R, Bilal U, Fuster V. Control de los factores de riesgo coronarios y terapias basadas en la evidencia: esfuerzos coordinados para la prevención cardiovascular en España. Rev Esp Cardiol. 2011;64:962-4.

  2. Heras M. Cardiopatía isquémica en la mujer: presentación clínica, pruebas diagnósticas y tratamiento de los síndromes coronarios agudos. Rev Esp Cardiol. 2006;59:371-81.

  3. Matthews RA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in Lealthy Women. Stroke. 2001;32:1104-11.

  4. Siniawski D, Masson W, Bluro I, Sorroche P, Scordo W, Krauss J y cols. Niveles plasmáticos de apolipoproteínas en una población saludable de la Argentina: Implicaciones en prevención cardiovascular. Rev Argent Cardiol. 2010;78(2).

  5. Ruíz-Fernández N, Espinoza Zavala M, González JC, Leal-Herrera U, Reigosa-Yaniz A. LDL oxidada circulante y anticuerpos contra LDL oxidada según niveles de ácido úrico en mujeres con exceso de peso. Arch Cardiol Mex. 2011;81(03):188-96.

  6. Quiles GJ. Predictores de crecimiento de placa a pesar de niveles bajos de LDL. J Am Coll Cardiol. 2010;55:2736-42.

  7. Laforest L, Sazonov V, Van Gansi E . Mixed dyslipidemias in primary care patients in France. Vasc Health Risk Manag. 2012;8:247-53.

  8. Santos-Gallego CG, Badimón JJ. Lipoproteínas de alta densidad y reducción de riesgo cardiovascular ¿promesas o realidades? Rev Esp Cardiol. 2012;65(04):305-8.

  9. Santos Gallego CG, Torres F, Badimón JJ. The benefical effects of HDL-c on atherosclerosis rationale and clinical results. Clin Lipidol. 2011;6:181-208.

  10. Cordero A, Moreno-Arribas J, Bertomeu-González V, Agudo P, Miralles B, Masiá MD, et al. Las concentraciones bajas de colesterol unido a las lipoproteínas de alta densidad, se asocian de manera independiente a enfermedad coronaria aguda en pacientes que ingresan por dolor toráxico. Rev Esp Cardiol. 2012(4);65:319-25.

  11. Badimón JJ, Ibáñez B. Incremento de las HDL como arma terapéutica en la aterotrombosis. Rev Esp Cardiol. 2010;63:323-33.

  12. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Prediction of cardio-and cerebro-vascular events in patients with subclinical carotid atheroclerosis and low HDL-cholesterol. Atherosclerosis. 2008;200:389-95.

  13. Millán J, Pedro-Botet J , Pintó X. Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento de riesgo residual por dislipidemia aterogénico. Clin Invest Arterioscl. 2011;23:230-9.

  14. Blackburn F, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G, et al. Angiographically-assessed coronary artery disease associates with HDL particle size in women. Atherosclerosis. 2012;223:359-64.

  15. Martínez Hervás S, Romero P, Pedro T, Ferri J, Real JT, Priego A, et al. Perímetro de cintura y factores de riesgo cardiovascular. Rev Esp Obesidad. 2008;6:97-104.

  16. Socarrás MM, Bolet M. Alimentación saludable y nutrición en las enfermedades cardiovasculares. Rev Cub Invest Bioméd. 2010;29:353-63.

  17. Coca A, Cia-Calvo L, Lozano JV, Inaraja V, Fernández-Pérez C, Navarro J, et al. Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de España. Estudio RIMHA. Epidemiología y Prevención. 2009;62:1022-31.

  18. Shao B. Site-specific oxidation of apolipoprotein A-I impairs cholesterol exfort by ABCA1, a key cardioprotective function of HDL. Biochimic et Biophysics Acta. 2012;1821:490-501.

  19. Haas MJ, Mooradian AD. Inflammation, high density lipoprotein and cardiovascular dysfunction. Curr Opin Infect Dis. 2011;24:265-72.

  20. Lowenstein CJ, Cameron SJ. High Density Lipoprotein metabolism and endothelial function. Curr Opin Endocrinol Diabetes Obes. 2010;17:166-70.

  21. Rosenson RS, Brewer B, Chapman M, Fazio S, Hussain M, Kontush A, et al. HDL Measure Particle Heterogeneity, Proposed Nomenclature, and Relation to Aterosclerotic. Cardiovascular Events. Clinical Chemestry. 2011;57(3):392-410.

  22. Walls GF, Karpe F. Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient? Expert Rev Cardiovasc Ther. 2011;9:987-97.

  23. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: The Framingham Study. Atherosclerosis. 1988;8:207-11.

  24. Bordalo A, Nobre A, Dantas M, Cavrino J. Elevated HDL is the main negative risk factor for coronary artery disease in the elderly patient with calcific aortic valve disease. Rev Portuguesa Cardiol. 2012;31(6):415-24.

  25. Llanes Echevarría José Ramón, Ortega Torres Yanela, Rodríguez Nande Lidia, Paredes Cordero Ángel, Mojena Morfa Guillermo, Ramírez López Milvio et al . Valor pronóstico de las fracciones lipídicas basales, en pacientes operados de revascularización miocárdica con circulación extracorpórea. Rev Cubana Cir [revista en la Internet]. 2011 Sep [citado 2012 Jul 26] ; 50(3): 324-332. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932011000300009&lng=es.




2020     |     www.medigraphic.com